0
selected
-
1.
Combination of locking plate and anti-osteoporosis drug for the treatment of senior osteoporotic proximal humeral fractures.
Chen, H, Zhou, Q, Liu, J
Pakistan journal of pharmaceutical sciences. 2017;(3(Special)):1129-1132
Abstract
To analyze and evaluate the clinical efficacy of the combination of locking plate and anti-osteoporosis drug for the patients with senior osteoporotic proximal humerus fractures. 120 patients with senior osteoporotic proximal humerus fractures were selected as research objects. According to the differences of treatment options, they were divided into two groups, i.e., 60 patients in observation group accepting the treatment of combination of locking plate and anti-osteoporosis drug, the other 60 patients in the control group accepting simple locking plate treatment. The treatment effect and final result between the two groups were compared. The follow-up result showed that the average fracture healing time of observation group was (94.5±4.2) days, with excellent treatment rate reaching to 93.33% (56/60); the average fracture healing time of control group was (116.5±3.8) days, with excellent treatment rate of 75% (45/60). The intergroup different was of statistical significance, wherein p<0.05. The treatment efficacy of the combination of locking plate and anti-osteoporosis drug for senior osteoporotic proximal humeral fractures is faster and more precise, which is worth being applied in clinical practice.
-
2.
[Efficacy of freeze-dried Lactobacilli in functional diarrhoe: a pilot study].
Andresen, V, Layer, P, Menge, D, Keller, J
Deutsche medizinische Wochenschrift (1946). 2012;(37):1792-6
Abstract
BACKGROUND AND OBJECTIVE The pathogenic role of the intestinal milieu for symptoms in functional bowel disorders such as functional diarrhea (FD) or associated pain and bloating in the irritable bowel syndrome (IBS) is the rationale for probiotic treatment approaches. It was the aim of this pilot study to test the effects of a lyophilisate from devitalized lactobacilli and their culture medium in patients with chronic FD. METHODS Following a one-week basal period, 22 patients mit FD (12 with IBS) were treated with Lacteol (2 capsules/day) for 4 weeks. Stool frequency, consistency (assessed by BSFS), urge, pain and bloating were recorded daily using a standardized symptom diary, and global relief was recorded weekly. RESULTS Daily stool frequency and number of days with urge were significantly decreased starting in week 1 (-0.6 ± 0.2/day; p = 0.005; and -1.3 ± 0.3 days, respectively; p = 0.001). This effect persisted throughout week 4 (-0.6 ± 0.2/day; p< 0.02; and -1.4 ± 0.5 days, respectively; p = 0.025). After 4 weeks, 50% of patients reported satisfactory symptom relief, including improvement in maximal stool consistency (BSFS: -0.3 ± 0.2; p = 0.04), and 43% of patients recorded a decrease in stool frequency of ≥ 25%. CONCLUSION These findings suggest a clinically relevant efficacy of Lacteol in a subgroup of patients with FD, particularly with regard to stool frequency, urge and stool consistency. As the study design does not allow to exclude that a placebo component might have contributed to these effects, the results should be corroborated in an larger, placebo-controlled trial.
-
3.
Influence of calcium and vitamin D supplementation on weight and fat loss in obese women.
Holecki, M, Zahorska-Markiewicz, B, Wiecek, A, Mizia-Stec, K, Nieszporek, T, Zak-Gołab, A
Obesity facts. 2008;(5):274-9
Abstract
BACKGROUND Dairy products not only reduce the risk of hypertension and cardiovascular diseases but may play a role in the treatment of obesity. As there is some evidence that calcium (Ca) and vitamin D may play a role in effective weight management, we decided to evaluate the influence of Ca and vitamin D supplementation on weight and fat loss in obese women. MATERIAL AND METHODS Forty obese women were enrolled in this study. Subjects were divided into 2 groups comparable with body mass index (BMI) and age. Group 1 was provided with calcium carbonate and 1-(OH)-vitamin D supplementation. Group 2 was provided with only a diet. Subjects participated in a 3-month weight reduction therapy (balanced diet, modification of life style, and regular physical exercise). Blood samples (serum concentration of Ca, phosphorus (P), parathormone (PTH), 25-(OH)-D3) and clinical characteristics (weight, height, BMI, body composition) were taken at baseline and after the 3-month program. RESULTS No significant differences of body weight, body fat content, serum parathormone, 25-(OH)-D3 concentration, and plasma total Ca and P concentration were observed between analyzed groups both before and after the treatment. Additionally, we did not observe any significant influence of Ca and vitamin D supplementation on weight and fat loss. CONCLUSION Ca plus vitamin D supplementation during a 3-month low caloric diet has no additional effect on weight and fat loss in obese women.
-
4.
Oral calcium administration attenuates thrombocytopenia in patients with dengue fever. Report of a pilot study.
Cabrera-Cortina, JI, Sánchez-Valdéz, E, Cedas-DeLezama, D, Ramírez-González, MD
Proceedings of the Western Pharmacology Society. 2008;:38-41
Abstract
Global climate change is one of the instigating and contributing factors for epidemic outbreaks of infectious diseases in human populations. In the years 2003 to 2005 the city of Tampico, in the northern state of Tamaulipas, Mexico, experienced recurrent outbreaks of dengue virus infections (DV) and the resulting dengue fever (DF). One of the hallmark symptoms of DF, which appears to worsen as the environmental temperature increases, is thrombocytopenia. In as much as it is a hallmark for hemorrhagic manifestations, thrombocytopenia is a useful sign to monitor the course of infected patients. Extracellular calcium (Ca2+ o) plays a key role in blood clotting; its chelation in vitro with ethylenediaminetetracetic acid (EDTA) or citrate prevents clotting, while exogenous recalcification of plasma leads to shortening of clotting time. In vivo, Ca2+ o is essential for platelet function and for the regulation of the immune response. In this work we report a significant increase (p<0.05) in the number of blood platelets of patients with clinical signs and symptoms of DF following oral administration of calcium carbonate (CAL, 1.2 to 1.8 g/day; n=10) when compared with a control group (CTL, n=10): 89 (46-132) versus 206 (155-257). Data expressed as mean value (95% confidence interval, C.I.) for x1000 cells/mm3. CAL also improved overall clinical condition and reduced by 36 % the duration of signs and symptoms of DF: 6.7-11.3 days, versus 11.5-16.6 days (95 % C.I., p<0.05) when compared with CTL patients. The possible mechanism of calcium attenuated thrombocytopenia and clinical improvement is discussed.
-
5.
[Early treatment of secondary hyperparathyroidism in moderate renal insufficiency: low-phosphorus diet versus calcium carbonate].
Aresté, N, Amor, J, Cambil, T, Salgueira, M, Sánchez-Palencia, R, Páez, C, Gómez, O, Palma, A
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 2003;:64-8
Abstract
Calcitriol deficiency and phosphorus retention are mechanisms involved in the pathogenesis of renal hyperparathyroidism. The aim of this study was to evaluate the effect of dietary phosphorus restriction versus calcium carbonate treatment for one month on PTH and calcitriol levels in patients with mild renal failure. We studied two groups of patients: Group I: 21 patients (14M/7F); mean age 61 years old; mean glomerular filtration rate 51 ml/min. Their diet contained phosphorus 700 mg/day. Group II: 30 patients (21M/9F); mean age 58; mean glomerular rate 56 ml/min. They were divided in two subgroups: 18 patients treated with calcium carbonate 2.5 g/day and 12 patients with 5 g/day. Serum PTH, calcitriol, 25(OH)D3, calcium, phosphorus and urinary excretion of calcium and phosphorus were measured before and after a 30 day period. The low phosphorus diet (Group I) resulted in a significant decrease in PTH levels (81.3 +/- 35 vs 71 +/- 39 pg/ml, p < 0.05) and significant increase in calcitriol levels (22.4 +/- 4.4 vs 33.4 +/- 7.5 pg/ml, p < 0.05). In our study calcium carbonate treatment (Group II) had no effect on PTH and calcitriol levels.
-
6.
Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin.
Bauman, WA, Shaw, S, Jayatilleke, E, Spungen, AM, Herbert, V
Diabetes care. 2000;(9):1227-31
Abstract
OBJECTIVE Of patients who are prescribed metformin, 10-30% have evidence of reduced vitamin B12 absorption. B12-intrinsic factor complex uptake by ileal cell surface receptors is known to be a process dependent on calcium availability Metformin affects calcium-dependent membrane action. The objective of this study was to determine the magnitude and mechanism of the reduction in serum vitamin B12 after metformin administration. RESEARCH DESIGN AND METHODS A comparative study design was employed using 2 groups (metformin and control). A total of 21 patients with type 2 diabetes received sulfonylurea therapy; 14 of these 21 patients were switched to metformin. Monthly serum total vitamin B12 measurements and holotranscobalamin (holoTCII) (B12-TCII) were performed. After 3 months of metformin therapy, oral calcium supplementation was administered. RESULTS Serial serum vitamin B12 determinations revealed a similar decline in vitamin B12 and holoTCII. Oral calcium supplementation reversed the metformin-induced serum holoTCII depression. CONCLUSIONS Patients receiving metformin have diminished B12 absorption and low serum total vitamin B12 and TCII-B12 levels because of a calcium-dependent ileal membrane antagonism, an effect reversed with supplemental calcium.
-
7.
Effects of phosphorus-containing calcium preparation (bone meal powder) and calcium carbonate on serum calcium and phosphorus in young and old healthy volunteers: a double-blinded crossover study.
Tsuboi, M, Shiraki, M, Hamada, M, Shimodaira, H
Journal of bone and mineral metabolism. 2000;(6):321-7
Abstract
To evaluate the effects of bone meal powder (BEC) on calcium and phosphorus metabolism, a calcium absorption test was conducted using a preparation of calcium carbonate (CAC) as the control drug. A total of 12 healthy volunteers, consisting of 6 younger (aged 20-29 years, 3 men and 3 women) and 6 older (aged 60-69 years, 3 men and 3 women) persons, were subjected to a double-blinded crossover study. Serum calcium (s-Ca) level significantly increased to 105.3% +/- 1.9% (P < 0.01 vs the basal value; mean +/- SD) from the basal value in the BEC group and to 104.4% +/- 2.7% (P < 0.01) in the CAC group at 3h post load. Urinary excretions of calcium (u-Ca/glomerular filtration rate, u-Ca/GF) after BEC and CAC load rose to 226.6% +/- 154.5% (P < 0.05) and 211.1% +/- 148.0% (P < 0.05), respectively. Serum phosphorus (s-P) levels after BEC load increased to 110.0% +/- 15.1% (P < 0.05), whereas that after CAC load showed no significant change (99.3% +/- 7.9%). On the other hand, urinary excretion of phosphorus (u-P/GF) after CAC load decreased to 60.0% +/- 32.4% (P < 0.01) and that in the BEC group showed no significant change (92.5% +/- 49.5%). The increase in s-Ca led to decrease in serum intact parathyroid hormone (i-PTH) level [77.3% +/- 33.4% (P < 0.05) for BEC and 69.5% +/- 20.3% (P < 0.01) for CAC] although s-P was increased by the BEC load. The responses to BEC and CAC administration were compared in the younger and the older groups. The responses in the younger and the older group showed fundamentally the same trends and to the same extent. However, the changes in serum ionized calcium (i-Ca) and i-PTH levels at 1.5 h post load were significantly smaller in the older group than in the younger group (P < 0.01; P < 0.05). The increment in s-P level after BEC load in the older group was larger than that in the younger group. In conclusion, BEC can modulate not only calcium but also phosphorus metabolism in both younger and older subjects. Further investigations are required to evaluate the effects of BEC on bone density and safety for renal function in long-term observations.